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Abstract
The current treatment of eumycetoma utilizing ketoconazole is unsatisfactory because of high recurrence rates, which often
leads to complications and unnecessary amputations, and its comparatively high cost in endemic areas. Hence, an effective
and affordable drug is required to improve therapeutic outcome. E1224 is a potent orally available, broad-spectrum triazole
currently being developed for the treatment of Chagas disease. E1224 is a prodrug that is rapidly converted to
ravuconazole. Plasma levels of E1224 are low and transient, and its therapeutically active moiety, ravuconazole is
therapeutically active. In the present study, the in vitro activity of ravuconazole against Madurella mycetomatis, the most
common etiologic agent of eumycetoma, was evaluated and compared to that of ketoconazole and itraconazole.
Ravuconazole showed excellent activity with MICs ranging between #0.002 and 0.031 mg/ml, which were significantly
lower than the MICs reported for ketoconazole and itraconazole. On the basis of our findings, E1224 with its resultant active
moiety, ravuconazole, could be an effective and affordable therapeutic option for the treatment of eumycetoma.
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Introduction
Mycetoma is a serious health problem with high morbidity. It is
endemic in subtropical areas and often leads to severe deformity
and disability [1]. The disease has long been disregarded by
international health organizations but was recently recognized by
WHO as a neglected tropical condition (http://www.who.int/
neglected_diseases/diseases/en/). One of the main problems of
eumycetoma is its recalcitrant nature, which necessitates pro-
longed antifungal therapy combined with massive and repeated
surgical debridement. In severe cases, amputation of the affected
part may be the only remaining treatment option [2]. Madurella
mycetomatis is the most common fungal pathogen causing
eumycetoma in arid climate zones, particularly in northeastern
Africa. The infection by M. mycetomatis is characterized by the
presence of black grains in tissue [3]. Previous reports showed that
this fungus was most susceptible to the azole class of antifungal
agents [4,5,6]. Ketoconazole and itraconazole are the most
frequently used drugs for the treatment of mycetoma. However,
therapy failure is common and high recurrence and amputation
rates are reported [7]. Another concern is that both the Food and
Drug Administration (FDA) and the European Medicines Agency
(EMEA) recently restricted the use of ketoconazole due to its toxic
side effects (http://www.fda.gov/Drugs/DrugSafety/ucm362415.
htm) [8], making the need for an alternative treatment for
eumycetoma even more urgent.
Since M. mycetomatis appeared to be most susceptible to the azole
class of antifungal agents, a new azole probably has the best
chance of meeting that need. A new azole currently under
development is ravuconazole. Ravuconazole is a broad-spectrum
triazole that showed activity against a wide array of fungal species
including Aspergillus spp., Candida spp., and Cryptococcus neoformans
[9,10]. Studies have shown that the efficacy of this new triazole
was comparable to that of posaconazole and voriconazole
[9,10,11]. In addition to antifungal activity, ravuconazole also
showed in vitro activity against the parasite Trypanosoma cruzi, the
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causative agent of Chagas disease, another neglected tropical
disease on the WHO list [12]. Eisai developed a prodrug of
ravuconazole (E1224) which has a simpler chemical structure, is
safe, and has a long half-life in humans [13]. These attributes will
reduce the costs of ravuconazole treatment and will make it an
affordable drug for people in endemic countries. In the present
study, we investigated the antifungal activity of ravuconazole (the
active moiety of E1224) against 23 isolates of Madurella mycetomatis.
Materials and Methods
Fungal isolates
The 23 isolates were obtained from 23 patients seen at the
Mycetoma Research Centre, University of Khartoum, Sudan, and
preserved in the collection of Erasmus Medical Centre, Rotter-
dam, and CBS (Fungal Biodiversity Centre), Utrecht, The
Netherlands. All the strains were previously collected and were
taken from the above mentioned collections for the study. The
identity of the strains was confirmed with a multi-locus analysis of
rDNA internal transcribed spacer and partial large subunit and
compared with M. mycetomatis type strain CBS 109801 [14]. Prior
to susceptibility testing, fresh cultures of the strains were made on
Sabouraud’s dextrose agar (SDA) plates which were incubated for
three weeks at 37 uC.
In vitro susceptibility testing
The in vitro activity of ravuconazole was determined using
the 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyla-
mino) carbonyl]-2H-tetrazolium hydroxide (XTT) broth mi-
cro-dilution assay to estimate the minimum inhibitory con-
centration (MIC) for the strains [15]. The method was
described and validated by Ahmed et al. for susceptibility
testing of M. mycetomatis using a standardized hyphal inoculum
[15]. For the assay, about 2 cm of fungal colonies grown on
SDA plates were scraped off and inoculated into tubes with
10 ml RPMI 1640 medium containing 0.35 g/liter L-gluta-
mine and 1.98 mM 4-morpholinepropanesulfonic acid
(MOPS). Prior to incubation, the fungal mass was sonicated
for 5 s at the maximum power of a sonicator (Beun de Ronde,
The Netherlands). Tubes were incubated for 7 days at 37 uC.
After incubation, mycelia were washed once with RPMI and
sonicated again for 5 s at the maximum power. The final
inocula were adjusted spectrophotometrically (660 nm; No-
vaspec II, Pharmacia Biotech, Cambridge, U.K.) to obtain
transmissions in the range of 69–71%. Ravuconazole was
kindly provided by Eisai Co., Ltd., as reagent-grade powder
and used in concentrations ranging from 0.002 to 2 mg/ml. In
addition to ravuconazole, MICs were also determined for
ketoconazole (Janssen Pharmaceuticals, Belgium) and itracon-
azole (Janssen) in concentrations ranging from 0.016 to 16 mg/
ml. The assay was carried out in round-bottom microtitre plate
where 100 ml of the inoculum were added to 2 ml of drug
concentrations. For each isolate drug free control and negative
control were included to define the end point reading.
Endpoint reading was done after 7 days of incubation at 37
uC using XTT; MICs were defined as the lowest concentration
with a minimum of 80% growth reduction. With the XTT
assay, 100% reduction in viable fungal mass could not be used
as an end-point, since a number of strains had pigments that
influenced the color intensity [15]. The 80% boundary was
found to correspond with the MICs obtained visually for the
fungistatic drug amphotericin B [15]. All experiments were
performed in duplicate on different days. Association between
MICs obtained for ravuconazole and the comparator azoles
were done using the Mann-Whitney test and Wilcoxon’s signed
rank test.
Results
As shown in Table 1, fifty percent of the strains were
inhibited by a concentration of 0.063 mg/ml (MIC50) for both
ketoconazole and itraconazole, while a concentration of
0.25 mg/ml (MIC90) was required to inhibit 90% of the strains.
Significantly lower MICs were obtained with ravuconazole in
comparison to ketoconazole and itraconazole (Mann-Whitney,
p,0.0001 for both comparisons), with MICs ranging from #
0.002 to 0.031 mg/ml (Fig. 1). Same results were obtained
when using Wilcoxon’s signed rank test [Z-value: -4.1973, p-
value is 0.00 for both drugs]. Moreover, there is no cross
susceptibility among strains showed low MICs for ravucona-
zole and those of ketoconazole and itraconazole. A concen-
tration of 0.004 mg/ml ravuconazole was needed to inhibit
50% of the strains, whereas 0.016 mg/ml was required to
inhibit 90% of them.
Discussion
In this study, we demonstrated that Madurella mycetomatis, the
most common etiologic pathogen for mycetoma, was highly
susceptible to ravuconazole with MICs ranging from #0.002
to 0.031 mg/ml. These MICs were not only considerably lower
than those found for ketoconazole and itraconazole in the
present study, but they were also lower than those reported for
voriconazole (0.016–1 mg/ml), posaconazole (0.03–0.125 mg/
ml), and isavuconazole (0.016–0.125 mg/ml) [4,5,6]. Only a
few reports are available regarding the susceptibility of other
eumycetoma causative agents towards ravuconazole. Studies
have shown that ravuconazole has inhibitory activity against
the black-grain eumycetoma species Exophiala jeanselmei and to
the saprobe Curvularia lunata that occasionally has been
observed in eumycetoma [10,16]. In contrast, resistance was
reported for the white-grain eumycetoma causative pathogens
Pseudallescheria boydii and Fusarium species [10,16,17]. Good
inhibitory activity of ravuconazole was reported for members
of Chaetomium, a genus that was found to be phylogenetically
close to the genus Madurella [14,18]. Low MICs were reported
for Chaetomium species ranging from 0.06 to 1 mg/ml, but these
values were higher than the results reported in this commu-
nication [18]. Studies of the in vitro activity of ravuconazole
against the more common pathogenic fungi, including Crypto-
coccus neoformans, Candida species, Aspergillus species, and the
Author Summary
Madurella mycetomatis is the most common etiologic
agent of eumycetoma worldwide. Treatment of this
infection is very difficult and associated with high
recurrence rates and low cure rates. Currently the
treatment consists of a combination of surgery and
antifungal therapy. Antifungal therapy is usually given
for at least one year. However, the commonly used
antifungal ketoconazole is too expensive for many patients
in endemic countries and has many side effects. In the
present study we evaluated the in vitro activity of the new
antifungal agent ravuconazole against M. mycetomatis. The
drug showed excellent in vitro activity against all tested
strains and its prodrug, E1224, might be a potential new
therapeutic option for eumycetoma caused by M. myce-
tomatis.
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dermatophytes, showed that the drug has activity comparable
to that of other triazoles [10,16,19,20]. Moreover, ravucona-
zole showed potent in vitro activity against the parasite
Trypanosoma cruzi [12]. Several studies have been conducted
to evaluate the in vivo efficacy of ravuconazole and E1224 using
animal models of aspergillosis, candidiasis, and cryptococcosis,
with each demonstrating encouraging activity of the drug
[21,22,23]. In addition, phase 1/2 clinical trials have shown
that ravuconazole and E1224 were well tolerated. Ravucona-
zole had a relatively long half-life of 4–8 days and the peak
plasma concentrations of the drug ranged from 1.20 to
6.02 mg/ml when 50–400 mg/day was administrated orally
for 14 days [24]. E1224 provides the advantage of more
favorable pharmacokinetics with a half-life of ravuconazole
(resulting from conversion of E1224 to ravuconazole) of 7.7 to
10.5 days and peak plasma levels of 3.7–379 mg/ml when 200–
400 mg/day was administrated orally for 14 days [25]. This
serum level of the drug is much higher than the concentration
needed to inhibit 90% of the M. mycetomatis strains in the
present study (MIC90 of 0.016 mg/ml). Furthermore, in rabbits
it was demonstrated that ravuconazole concentrations in the
liver, adipose tissue, marrow, kidney, lung, brain and spleen
exceeded concurrent plasma concentrations [26]. Moreover,
high concentrations were also detected in lung and uterus of
rat [27]. Due to these high levels of the drug in tissue, good
therapeutic efficacy was obtained in animal models with
pulmonary and disseminated aspergillosis, candidiasis, histo-
plasmosis, intracranial and disseminated cryptococcosis
[21,23,28,29]. Based on the in vitro susceptibility generated in
this study, the next step will be to study the efficacy of
ravuconazole in an animal model of mycetoma.
We conclude that ravuconazole has potent in vitro activity
against M. mycetomatis. Compared to other infectious fungi,
Madurella is exceptionally susceptible to this drug. With its
favorable pharmacokinetic properties and low toxicity, E1224
with its resultant active moiety, ravuconazole, could be a
Figure 1. In vitro activities of ketoconazole (KTC), itraconazole (ITC), and ravuconazole (RVC) against 23 isolates of Madurella
mycetomatis represented by MICs.
doi:10.1371/journal.pntd.0002942.g001
Table 1. In vitro susceptibility of Madurella mycetomatis to ketoconazole, itraconazole, and ravuconazole.
Antifungal agent GMa MIC (mg/ml) MIC Range (mg/ml) MIC50 (mg/ml) MIC90 (mg/ml)
Ketoconazole 0.072 0.031–0.25 0.063 0.25
Itraconazole 0.063 #0.016–0.5 0.063 0.25
Ravuconazole 0.005 #0.002–0.031 0.004 0.016
aGM, geometric mean.
doi:10.1371/journal.pntd.0002942.t001
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promising antifungal agent for treatment of eumycetoma. A
clinical trial is now required for an in vitro-in vivo correlation of the
activity of the drug.
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